Eur Rev Med Pharmacol Sci 2016; 20 (13): 2799-2804

NKD2 a novel marker to study the progression of osteosarcoma development

X.-Z. Sun, Y. Liao, C.-M. Zhou

Department of Anatomy and Histoembryology, Peking University Health Science Center, Beijing, China. zhouchangman2010@hotmail.com


OBJECTIVE: Osteosarcoma is the most frequent metastatic bone tumor in the current era. An effective novel marker is essential at the current scenario for the identification of the tumor and to treat them in the early stage of osteosarcoma.

PATIENTS AND METHODS: In the present study, patients having metastatic and non-metastatic osteosarcoma samples were collected from the 23 patients along with the control. Microarray analysis was performed on both samples. The results were validated using Western blot analysis.

RESULTS: Microarray analysis confirms the up-regulation of NKD2 gene in the progression of osteosarcoma development. The results were validated using western blot analysis. Microarray in accordance with Western blot analysis helps to validate the expression of NKD2 in the progression of osteosarcoma development.

CONCLUSIONS: In short, NKD2 is the key molecular marker to study the progression of osteosarcoma development, and it may be used for better prognosis of the disease in early stage.

Free PDF Download

To cite this article

X.-Z. Sun, Y. Liao, C.-M. Zhou
NKD2 a novel marker to study the progression of osteosarcoma development

Eur Rev Med Pharmacol Sci
Year: 2016
Vol. 20 - N. 13
Pages: 2799-2804